

Contact Information 531 S. Spring Street
Burlington, NC 27215
Telephone: 336 436-7716
Cell: 303 907 5497
E-mail: adcockd@labcorp.com

EDUCATION:

1979 – Bachelor of Science, Microbiology

High Honors
Michigan State University
East Lansing, Michigan

1983 – Doctor of Medicine

Michigan State University
East Lansing, Michigan

1987 – Pathology Residency

University of Colorado
Denver, Colorado

PROFESSIONAL EXPERIENCE:

1987 – 1989 Chief, Hematology/Blood Bank

Veterans Administration Medical Center
Denver, Colorado

1988 – 1989 Consulting Clinical Pathologist

National Jewish Center for Immunology and Respiratory Medicine
Denver, Colorado

1989 – 2000 Staff Pathologist

Colorado Permanente Medical Group

1991 – 1993 Regional Departmental Chief of Pathology and Laboratory Director

Colorado Permanente Medical Group

1990 – 2000 Consulting Pathologist

Colorado Coagulation Consultants
Denver, Colorado

2005 – 2007 Medical Director/Laboratory Director

Esoterix Molecular Genetics
Eden Prairie, MN

2005 – Present: Co-Discipline Director, Special Coagulation

Laboratory Corporation of America

2007 – 2015: Medical Director/Laboratory Director

Esoterix Hemex
Phoenix Arizona

2001 – 2017: Medical Director/Laboratory Director

Esoterix Coagulation

Englewood, Colorado

2017 – Present: Chief Medical Officer LabCorp Diagnostics

Burlington North Carolina

PROFESSIONAL ACTIVITIES:

Kaiser Permanente National Purchasing Organization

- **1996 – 2000**
Chair Coagulation Sourcing and Standards Committee

Food and Drug Administration

- **1997 –2003**
Center for Devices and Radiological Health
Ad Hoc Advisory Committee Member
- **2007 – 2011**
Chair Hematology and Pathology Devices Panel
- **2013 – 2014**
Center for Devices and Radiological Health
Ad Hoc Advisory Committee Member
- **2015-Present**
Chair Hematology and Pathology Devices Panel

Clinical Laboratory Standards Institute/National Committee for Clinical Laboratory Standards

- **1998 – 2002**
Member Subcommittee on Coagulation
- **2000 – 2005**
Chair Subcommittee on Plasma Calibration for PT Testing (H54)
- **2004 – 2008**
Member – Area Subcommittee on Hematology
- **2005 – 2008**
Subcommittee on Evaluation of Coagulometers
- **2006 – 2008**
Chair, Working Committee on Plasma collection transportation and storage for hemostasis testing (H21)
- **2008 – 2009**
Vice Chair – Area Committee on Hematology
- **2008 – 2011**
Member Subcommittee on Quantitative D-dimer
- **2010 – 2013**

Updated 12Jul2018

Chair – Area Committee on Hematology

- **2009 – 2015**

Chair – Working Committee on von Willebrand Factor Antigen and Activity (H51)

American Society of Hematology

- **2010 – 2013**

CLSI Representative – Committee on Practice

American Society for Clinical Pathology

- **1999 – 2002**

Member of Hematology Council on Continuing Education

- **2002 – 2005**

Chair Hematology Council on Continuing Education

- **2000 – 2006**

Check Sample Committee

- **2007 – 2008**

Vice Chair Teleconference Committee

- **1995 – 2008**

Teleconference Committee

College of American Pathologists

- **2003 – Present**

Phlebotomy Committee

- **2008 – 2013**

Coagulation Resource Council, member

- **2017 – Present**

Publications Committee

North American Specialized Coagulation Laboratory Association

- **2006 – 2010**

Secretary

- **2011 – 2014**

Treasurer

- **2015 – 2016**

Vice President

- **2017 – Present**

President

American Board of Pathology

- **2015 – Present**

Hematology Test Development and Advisory Committee

1987 – Present: *College of American Pathologists, Fellow and Inspector*

1989 – Present: *American Society of Clinical Pathologists*

1995 – Present: *American Society of Hematology*

1997 – Present: *International Society on Thrombosis and Hemostasis*

1991 – 1996: *Colorado Association of Continuing Medical Education (CACMLE), Board of Directors. Vice President and President*

1996 – 1999: *American Thrombosis Association, Board of Directors, Vice President*

2000 – 2003: *American Thrombosis Association, Board of Directors, President*

AWARDS RECEIVED:

Phi Beta Kappa – Michigan State University

Tower Guard Honor Society – Michigan State University

American Medical Women's Association Award for Scholastic Achievement

LICENSURE AND CERTIFICATION:

1984 – National Board of Medical Examiners

1987 – American Board of Pathology, Clinical and Anatomical Pathology

1986 – 1989 Licensure State of Wyoming

1986 – Licensure State of Colorado

2003 – Licensure State of New Jersey

2004 – 2017 Licensure State of Minnesota

2007 – 2017 Licensure State of Arizona

ACADEMIC APPOINTMENTS:

1987 – 1989 – Assistant Professor, University of Colorado

1989 – 2006 – Clinical Assistant Professor, University of Colorado

INVITED SPEAKER:

American Society for Clinical Pathology

- 1992: Teleconference – Basic Hemostasis
- 1994: Teleconference – Hereditary Hypercoagulability
- 1995: Workshop – Coagulation Update
- 1996: Teleconference – Case Studies in Hemostasis

- 1997: Workshop – Case Studies in Coagulation
- 1998: Workshop – Preanalytical Variables in the Coagulation Laboratory
- 1999: Teleconference – Laboratory Monitoring of Heparin and Commonly Used Heparin – Like Anticoagulants
- 2000: Teleconference – Preanalytical Variables in the Coagulation Laboratory
- 2001: Teleconference – Determining Heparin Therapeutic Range
- 2002: Teleconference – Lupus Anticoagulant: The Laboratory Evaluation, Diagnosis and Potential Pitfalls
- 2003: Teleconference – The Patient is Bleeding, but the Routine Coagulation Tests are All Normal – Now What?
- 2004: Teleconference – Ask the Experts
- 2005: Web Conference – Pitfalls in the Laboratory Evaluation of Thrombophilia
- 2005: National Meeting – Workshop – An Overview of Hemostasis
- 2006: National Meeting – Workshop – An Overview of Hemostasis
- 2006: Teleconference – Immunoassays in the Evaluation of Anti-Phospholipid Antibodies – Which assays should be used and their clinical relevance
- 2007: National Meeting – Workshop – An Overview of Hemostasis
- 2007: Workshop – An Overview of Hemostasis
- 2007: Teleconference – An Introduction to Pharmacogenomics and its Relationship to Anti-Vitamin K (warfarin) Therapy
- 2008: Teleconference: Plasma Mixing Studies
- 2008: National Meeting – Workshop – Companion Diagnostics in Coagulation
- 2008: National Meeting – Stump the Stars
- 2009: Teleconference – Thrombophilia
- 2009: Workshop – An Overview of Hemostasis
- 2009: ASCP Workshops for Laboratory Professionals, Chicago, IL
- 2009: ASCP Annual Meeting – Overview of Hemostasis, Chicago, IL
- 2010: ASCP Annual Meeting – Overview of Hemostasis, San Francisco, CA
- 2010: Teleconference – Bleeding Disorders: Clinical Presentation and Laboratory Diagnosis
- 2010: Workshop – Overview of Hemostasis, San Francisco, CA
- 2011: Workshop – Overview of Hemostasis, Phoenix, AZ
- 2012: Workshop – Overview of Hemostasis, Baltimore, MD
- 2013: Workshop – Overview of Hemostasis, San Francisco, CA
- 2014: Webinar – Preanalytic Variables in the Coagulation Laboratory
- 2014: Webinar – Antiphospholipid Antibodies Update
- 2018 Workshop – Overview of Hemostasis, Phoenix, AZ

OTHER

- 1994 – 1998: Director CACMLE Teleconference Series in Hemostasis, Denver, Colorado
- 1996 – 1999: Coarse Director CACMLE, Hematology in the Hills, Breckenridge, Colorado
- 1997: Temple University Hemostasis and Thrombosis Update – Monitoring Oral Anticoagulant Therapy
- 1998: Temple University Hemostasis and Thrombosis Update – Laboratory Monitoring of Heparin Therapy
- 2000: Temple University Hemostasis and Thrombosis Update: Use of the D-dimer Assay in the Evaluation of Venous Thrombosis
- 2002: Temple University Hemostasis and Thrombosis Update: Recent Advances in the Special Coagulation Laboratory
- 2002: Louisiana Coagulation Conference, New Orleans, LA
- 2003: Grand Rounds: New York Medical Center, Valhalla, NY
Maui Memorial Medical Center, HI
Mid-Ohio Hematology/Oncology, Cincinnati, OH
- 2004: Grand Rounds: Western Baptist Hospital, Paducah, KY
Hackensack University Medical Center, NJ
Denton Regional Medical Center, TX
Maui Memorial Medical Center, HI
Bozeman Deaconess Hospital, Bozeman, MT
- 2005: Grand Rounds: North Shore Hospital, Boston, MA
Kishwaukee Community Hospital, DeKalb, IL
- 2005: New York State Society of American Medical Technologists Spring Meeting, Flushing, NY
- 2005: International Society for Laboratory Hematology, San Francisco, CA
- 2005: Mayo Medical Laboratories/NASCOLA Coagulation Testing Quality Conference, Rochester, MN
- 2005: International Society on Thrombosis and Hemostasis XXth Congress, Subcommittee on Control of Anticoagulation, Sydney, Australia
- 2005: BioMérieux Southern California Knowledge Symposium
- 2006: Grand Rounds: Benefils Healthcare, Great Falls, MT
Harborview Mercy Hospital, Fort Smith, AR
- 2006: William Beaumont Hospital 15th Annual Symposium on Molecular Pathology, Troy, MI
- 2006: Dade Behring Hemostasis Fall Series, Las Vegas, NV
- 2007: Dade Behring Hemostasis Spring Series, Charleston, NC
Dade Behring Symposium: Geneva Switzerland
Dade Behring Symposium: Towchester United Kingdom
- 2007: International Society for Laboratory Hematology, San Francisco, CA
- 2007: Mayo Medical Laboratories/NASCOLA Coagulation Testing Quality Conference, Rochester, MN
- 2008: ASCLS Regional Meeting (February), Phoenix, AZ
- 2008: Grand Rounds: St. Jude Children’s Research Hospital, Memphis, TN
John C. Lincoln Hospital, Phoenix, AZ
- 2008: ASCLS Regional Meeting (May), Phoenix, AZ

2008: Siemens Hemostasis Spring Series, St. Louis, MO
2008: Midwest Thrombosis Hemostasis, Indianapolis, IN
2009: Siemens Hemostasis, Hematology and Urinalysis Diagnostic Conference, Las Vegas, NV
2009: Mayo Medical Laboratories 2009 Coagulation Testing Quality Conference and Spring Training Workshop, Rochester, MN
2009: Midwest Coagulation Hemostasis Symposium, Course Director, Indianapolis, IN
2009: UK NEQAS for Blood Coagulation Annual Scientific Meeting, Sheffield Hallam University, Sheffield, UK
2009: Advances in Molecular Diagnostics and Hemostasis, St. Luke's Hospital of Kansas City – Kansas City, MO
2010: Grand Rounds: Littleton Adventist Hospital, Littleton, Co
Cook Children's Hospital, Dallas, TX
2010: HTRS & NASCOLA Scientific Symposium, Chicago, IL
2010: Midwest Coagulation 2010 Hemostasis Symposium, Muncie, IN
2010: UK NEQAS for Blood Coagulation Annual Scientific Meeting, Sheffield Hallam University, Sheffield, UK
2010: American Medical Technology Educational Program and National Meeting, Las Vegas, NV
2010: Drexel University School of Medicine, Philadelphia, PA
2011: Grand Rounds: Barrow's Neurological Institute, Phoenix, AZ
2011: Grand Rounds: Our Lady of Lourdes Medical Center, Camden, NJ
2011: ISLH XXIVth International Symposium on Technological Innovations in Laboratory Hematology, New Orleans, LA
2011: Siemens Hemostasis Spring Series, Las Vegas, NV
2011: Regional Laboratory Network Educational Conference, "How to Investigate a Prolonged PTT or PT" and "Laboratory Investigation of Hypercoagulability", Blessing Hospital Laboratory, Quincy, IL
2011: American Society of Hematology Friday Satellite Symposia, Innovations in Laboratory Medicine: Therapeutic Assessment, San Diego, CA
2012: Grand Rounds: Rose Medical Center, Denver, CO
2012: CLCC Annual Workshop, Pre-Analytical Variables in the Hemostasis Laboratory, CO
2012: Mayo Coagulation Testing Quality Conference & Wet Workshop, Rochester, MN
2012: Texas Children's Hospital, Dallas, TX
2012: The Netherlands ECAT Foundation Meeting: Leiden, The Netherlands
2012: American Society of Hematology Educational Sessions: Pearls and Pitfalls in the Hemostasis Laboratory, Atlanta, GA
2012: Diagnostica Stago Boston Symposium
2013: Siemens Hemostasis Spring Series, New Orleans, LA
2013: Diagnostica Stago Southeastern Symposium
2013: Diagnostica Stago Northwestern Symposium
2013: Ohio State Pathology Annual Meeting
2014: Texas Society of Pathologists Annual Meeting
2014: Grand Rounds: St. Luke's, Houston, TX

2015: UK NEQAS for Blood Coagulation Annual Scientific Meeting, Sheffield Hallam University, Sheffield, UK
2015: ISLH XXVth International Symposium on Technological Innovations in Laboratory Hematology, New Orleans, LA
2015: ISTH 61st Annual SSC Meeting: Thrombophilia Testing in the United States, Toronto, Canada
2015: AACC: Pearls of Coagulation, webinar.
2016: AACC National Meeting, PA
2016: World Federation of Hemophilia National World Congress, Orlando FL
2016: American Society Pediatric Hematology/Oncology, Minneapolis, MN
2016: Grand Rounds: Mount Sinai Hospital, Miami, FL
2017: CAP Today Webinar: Laboratory Diagnosis and Therapeutic Monitoring in Hemophilia: Problems, Pitfalls, and Testing Pearls
2017: ISLH XXVIIth International Symposium on Technological Innovations in Laboratory Hematology, Honolulu HI
2017: Mayo Medical Laboratories Conference on Bleeding and Clotting Disorders, Rochester MN
2017: Global Summit on Preanalytical Variables, Charlotte NC
2018: Thrombosis Hemostasis Summit of North America, San Diego CA
2018: NEQAS, Sheffield UK

RESEARCH EXPERIENCE:

1977 – 1979: Michigan State University Department of Biochemistry
1980 – 1981: Michigan State University Department of Medicine
Histocompatibility Laboratory
1987 – 1989: Awarded VA Research Advisory Group Grant on Lupus Anticoagulant Induced Thrombosis
1994 – 2000: Veteran's Administration Medical Center Coagulation Research Laboratory

PEER REVIEWED PUBLICATIONS:

1. Roth JC, Adcock KA, Adcock DM. Bone formation in metastatic transitional cell carcinoma: detection with technetium – 99m methylene diphosphate. J Nuc Med 1988;29:1462-1463.
2. Marlar RA, Adcock DM. Clinical evaluation of Protein C: A comparative review of antigenic and functional assays: Hum Path 1989;20:1040-1047.
3. Marlar RA, Adcock DM, Madden RM: Hereditary dysfunctional protein C molecules (type II): assay characterization and proposed classification: Thromb Haemost 1990;63:375-379.
4. Marlar RA, Adcock DM (Editors): Purpura fulminans and skin necrosis. Semin Throm Hemost 1990;16(4).
5. Adcock DM, Hicks MJ: Dermathopathology of skin necrosis associated purpura fulminans. Semin Throm Hemost 1990;16:276-287.

6. Adcock DM, Brozna JP, Marlar RA. Proposed classification and pathologic mechanisms of purpura fulminans and skin necrosis. *Semin Thromb Hemost* 1990;16:327-334.
7. Hicks JM, Adcock DM, Marlar RA. The potential for acquired coagulopathies with methylenethiatetrazole cephalosporins. *Primary Care Bulletin*. 1990;5:30-33.
8. Marlar RA, Adcock DM. Protein C replacement therapy as a treatment modality for homozygous protein C deficiency. In: *Advances in Applied Biochemistry*. 1990. Vol II. 165-178.
9. Schroyer K, Svedlow GS, Adcock DM. Mycotic Pseudoaneurysm of the thoracic aorta with purulent pericarditis. *J Cardiovasc Path* 1990;3:347-352.
10. Marlar RA, Adcock DM. APTT reagent sensitivity to the presence of lupus anticoagulant. *Arch of Path and Lab Med* 1992;116:837-840.
11. Adcock DM, Kressin D, Marlar RA. The effect of 3.2 vs 3.8% sodium citrate concentration on routine coagulation testing. 1997; *AJCP* 107:105-110.
12. Adcock DM, Kressin D, Marlar RA. Are discard tubes necessary in coagulation studies? *Lab Med* 1997;28:530-533.
13. Adcock DM, Kressin D, Marlar RA. Minimum specimen volume requirements for routine coagulation testing. Dependence on citrate concentration. *AJCP* 1998;109:595-599.
14. Adcock DM, Fink L, Marlar RA. A laboratory approach to the evaluation of hereditary hypercoagulability. *AJCP* 1997;108:434-449.
15. Adcock DM, Marlar RA. The effect of time and temperature variables on routine coagulation testing. *Blood Coagul Fibrinolysis* 1998;9:463-470.
16. Adcock DM, Duff S. Enhanced standardization of the international normalized ratio (INR) through the use of plasma calibrants – A concise review. *Blood Coagul Fibrinolysis* 2000;11:1-8.
17. Adcock DM, Joiner-Maier D. An automated, rapid ELISA for determination of D-dimer in the evaluation of venous thrombosis. *Am Clin Lab* 1999;18(10):6.
18. Adcock DM, Johnston M. Evaluation of frozen plasma calibrants for enhanced standardization of the international normalized ratio (INR): A multi-center study. *Thromb Haemost* 2002;87(1):74-79.
19. Wolf SJ, McCubbin TR, Feldhaus KM, Faragher JP, Adcock DM. The role of wells criteria and the D-dimer assay in the evaluation of patients with suspected pulmonary embolism. *Ann Emerg Med* 2004 May;35(6):364-367.
20. Pantanowitz L, Bauer K, Tefs K, Schuster V, Balogh K, Pilch BZ, Adcock DM, Kocher O. Ligneous (pseudomembranous) inflammation of the female genital tract associated with type-1 plasminogen deficiency. *Int J Gyn Pathol* 2004 Jul;23(3):292-295.
21. Bethel M, Adcock DM. Laboratory evaluation of prolonged APTT and PT. *Lab Med* 2004 May;35(5):285-291.
22. Adcock D, Ramanathan R. The Fluid and Tissue Phases of the Plasminogen System. *Laboratory Medicine* 2004;6(35): 364-367.
23. Adcock DM, Koftan C, Crisan D, Kiechle FL. Effect of polymorphisms in the cytochrome P450CYP2C9 gene on warfarin anticoagulation. *Arch Pathol Lab Med*. 2004 Dec;128:1360-63.
24. Adcock DM. Guest Editorial: Issues in the evaluation and management of thromboembolic disease. *Journal of Clinical Ligand Assay*. 2005;28:121-122.

25. Palen TE, Adcock DM. Performance characteristics of three quantitative d-dimer assays for outpatient evaluation of venous thromboembolism and its use in a clinical guideline for a group model HMO. *Journal of Clinical Ligand Assay*. 2005;28:123-129.
26. Gardiner C, Kitchen S, Dauer RJ, Kottke-Marchant K, Adcock DM. Recommendations for evaluation of coagulation analyzers. *Laboratory Hematology*. 2006;12:32-38.
27. Adcock DM, Bethel M, Valcour A. Diagnosing von Willebrand disease: A large reference laboratory's perspective. *Semin Thromb Hemost*. 2006;32(5):472-479.
28. Adcock DM. Is there a genetic relationship between arterial and venous thrombosis? *Clin Lab Sci*. 2007;20(4):221-223.
29. Webster PS, Oleson Jr FB, Paterson DL, Arkin CF, Mangili A, Craven DE, Adcock DM, Lindfield KC, Knapp AG, Martone WJ. Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results. *Blood Coagul Fibrinolysis*. 2008;19:32-38.
30. O'Brien PJ, Ramanathan R, Yingling JM, Baselga J, Rothenburg ML, Carducci M, Daly T, Adcock DM, Lahn M. Analysis and variability of TGF alpha measurements in cancer patients with skeletal metastases. *Biologics: Targets & Therapy* 2008;2(3):563-569.
31. Adcock DM, Fink LM, Marlar RA, Cavallo F, Zangari M. The hemostatic system and malignancy. *Clin Lymphoma Myeloma* 2008;8:230-236.
32. Favalaro EJ, Lippi G, Adcock DM. Preanalytical and post analytical variables: The leading causes of diagnostic error in hemostasis? *Semin Thromb Hemost* 2008;34:612-634.
33. Lippi G, Salvagno GL, Gelati M, Adcock DM, Montagnana M, Guidi GC, Favalaro EJ. Identification of the sample matrix in centrifuged specimens referred for laboratory testing. *Ligand Assay* 2008;13(2):131.
34. Favalaro EJ, Adcock DM. Standardization of the INR: How good is your laboratory's INR and can it be improved? *Semin Thromb Hemost* 2008;34:593-603.
35. Xu D, Alipio Z, Fink LM, Adcock DM, Yang J, Ward D, Ma Y. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. *Proc Natl Acad Sci USA* 2009;106(3):808-813.
36. Lippi G, Salvagno G, Adcock DM, Franchini M, Favalaro EJ. Preanalytical variability of coagulation testing. *Ital J Med* 2009;5:1-8.
37. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in cancer patients receiving anti-angiogenesis agents. *J Clin Oncol* 27 2009;1-9.
38. Lippi G, Salvagno GL, Adcock DM, Gelati M, Guidi GC, Favalaro EJ. Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample. *Int J Lab Hematol* 2010;23(1):132-137.
39. Bonar R, Favalaro EJ, Adcock DM. Quality in coagulation and haemostasis testing. *Biochemia Medica* 2010;20(2):184-199.
40. Alipio Z, Adcock DM, Waner M, Fink L, Ward D, Ma Y. Sustained factor VIII production in hemophilic mice 1 year after engraftment with induced pluripotent stem cell-derived factor VIII producing endothelial cells. *Blood Coagul Fibrinolysis* 2010;21:502-504.
41. Adcock DM, Casciato D. Factor X Deficiency. *Clin Lab Sci* 2010;23(3):131-133.
42. Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, Paz L, Ma Y, Ward DC, Vogelzang NJ, Fink LM. Increases in quantitative D-dimer levels correlate

- with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer; *Am J Clin Pathol* 2010 Dec;134(6):964-969.
43. Cunningham MT, Olson JD, Chandler WL, Van Cott EM, Eby CS, Teryua J, Hollensead SC, Adcock DM, Allison PM, Kottke-Marchant KK, Smith MD. External quality assurance of antithrombin, protein c and protein s assays: Results of the College of American Pathologists proficiency testing program in thrombophilia. *Arch Pathol Lab Med* 2011;135:227-232.
 44. Barriere SL, Goldberg R, Jac JW, Higgins DL, Macy PA, Adcock DM. Effects of telavancin on coagulation test results. *Int J Clin Pract* 2011;65(7):784-789.
 45. Favaloro EJ, (Adcock) Funk DM, Lippi G. Preanalytical variables in coagulation testing associated with diagnostic errors in hemostasis. *Laboratory Medicine* February 2012;43(2):1-10.
 46. Favaloro EJ, Bonar R, Chapman K, Mering M, (Adcock) Funk DM. Differential Sensitivity of von Willebrand factor 'activity' assays to large and small VWF molecular weight forms: A cross-laboratory study comparing ristocetin cofactor, collagen binding and monoclonal antibody based assays. *J Thromb Haemost* 2012;10:1043-54.
 47. Fritsma GA, Dembitzer FR, Randhawa A, Marques MB, Van Cott EM, Adcock-Funk D, Peerschke EL. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization. *Am J Clin Pathol* 2012;137:904-908.
 48. Cunningham MT, Olson JD, Chandler WL, Van Cott EM, Eby CS, Teruya J, Hollensead SC, Adcock DM, Allison PM, Kottke-Marchant KK, Smith MD. External quality assurance of fibrinogen assays using normal plasma. *Arch Pathol Lab Med* 2012;136:789-795.
 49. Adcock-Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. *Semin Thromb Haemost* 2012;38:576-585.
 50. Adcock DM. Coagulation assays and anticoagulant monitoring. *Hematology* 2012. American Society of Hematology Education Program Book: 460-465.
 51. Lippi G, (Adcock) Funk DM, Favaloro EJ. Discard tube for coagulation testing: the debate continues. *Blood Coagul Fibrinolysis* 2012;23(6):572-573.
 52. Adcock DM, Gosselin B, Kitchen S, Dwyre D. The Effect of Dabigatran on Select Specialty Coagulation Assays. *Am J Clin Pathol*. 2013;139:102-109.
 53. Lippi G, Salvagno GL, (Adcock) Funk DM, Guidi GC, Favaloro EJ. Experimental study of blood tubes under filling for routine coagulation testing. *Biochimica Medica* 2013;23(1):A1
 54. Lippi G, Rossi R, Ippolito L, Zobbi V, Azzi D, Pipitone S, Favaloro E, Adcock Funk D. Influence of residual platelet count on routine coagulation, factor VIII, and factor IX testing in post freeze-thaw samples. *Semin Thromb Hemost*. 2013;39:834-839.
 55. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamics study based on peak and trough levels. *J Thromb Haemost*. 2013;11:1493-1502.
 56. Moser KA, Adcock DM. Pitfalls in special coagulation testing: three illustrative case studies. *Int J Lab Hematol*. 2013;35(3):334-8. doi: 10.1111/ijlh.12067.

57. Daves M, Giacomuzzi K, Tagnin E, Jani E, Adcock DM, Favalaro EJ, Lippi G. Influence of centrifuge brake on residual platelet count and routine coagulation tests in citrated plasma. *Blood Coag and Fibrin*. 2014;25(3):292-5.
58. Francart S, Hawes E, Deal Allison, Adcock D, Gosselin R; Jeanneret C, Friedman K, Moll S. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. *Thromb Haem*.2014. 111;1133-40.
59. Gosselin R, Hawes E, Moll S, Adcock D. Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses. A prospective study based on peak and trough levels. *Am J Clin Pathol* 2014;141:262-267.
60. Gosselin R, Adcock D, Francart S, Moll S. Comparison of Anti-Xa and Dilute Russell's Viper Venom Time (DRVVT) Assays in Quantifying Drug Levels in Patients on Therapeutic Doses of Rivaroxaban. *Arch Pathol Lab Med*. 2014;138:1680–1684; doi: 10.5858/arpa.2013-0750-OA).
61. Moser KA, Adcock DM. Chromogenic factor VIII activity assay. *Am J Hematol*. 2014;89:781-84.
62. Schreiber A, Schindler R, Adcock-Funk DM, Kahl A. The Case of a 48-year-old man with pulmonary-renal syndrome. *Kidney International*. 2015;87:667-668.
63. Gosselin RC, Adcock DM, Hawes EM, Francart SJ, Grant RP, Moll S. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. *Thrombosis and Haemostasis*. 2015;113;77-84.
64. Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM. Heparin calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? *Annals of Pharmacotherapy*. 2015;49(7)777-83. doi:10.1177/1060028015578451.
65. Adcock DM, Favalaro EJ. Pearls and Pitfalls in Factor Inhibitor Assays. *Int J Lab Hem*. 2015;37(1),52-60. doi:10.1111/ijlh.12352.
66. Gosselin RC, Adcock DM. Assessing Non-vitamin K Antagonist Oral Anticoagulants (NOACs) in the Laboratory. *Int J Lab Hem*. 2015;37(1),46-51. doi:10.1111/ijlh.12350.
67. Hillarp A, Friedman K, Adcock-Funk DM, Tiefenbacher S, Nichols W, Dong C, Stadler M, Schwartz B. Comparison of several von Willebrand factor activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method. *Hemophilia*. 2015. doi:10.1111/hae.12703.
68. Adcock DM, Gosselin RC. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. *Thrombosis Research*. 2015;136(1),7-12. doi:10.1016/j.thromres.2015.05.001.
69. Bern MM, Hazel D, Reilly DT, Adcock DM, Hou L. Effects of anticoagulation on markers of activation of clotting following major orthopedic surgery. *International Journal of Laboratory Hematology*. 2015. doi: 10.1111/ijlh.12384.
70. Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurement in Patients Receiving Rivaroxaban: can this test be used to quantify drug level? *Ann Pharmacother*. 2015 Jul;49(7):777-83. doi:10.1177/1060028015578451.

71. Longstaff C, Adcock DM, Olson JD, Jennings I, Kitchen S, Mutch N, Meijer P, Favalaro EJ, Lippi G, Thachil J. Harmonisation of D-dimer - A call for action. *J Thromb Res*. 2015;Jan(137),219-20.
72. Gosselin RC, Adcock DM. The Laboratory's 2015 Perspective on DOAC Testing. *J Thromb Haemost*. 2016. doi: 10.1111/jth.13266.
73. Gosselin RC, Adcock DM. Comment: Analysis of the influence of dabigatran on coagulation factors and inhibitors. *Int J Lab Hematol*. 2016 Feb;38(1):e4. doi: 10.1111/ijlh.12439.
74. Teruya M, Soundar E, Hui SR, Eldin K, Adcock D, Teruya J. PIVKA-II correlates with INR but not protein C or protein S concentrations in cord blood among newborns. *Journal of Neonatal-Perinatal Medicine*. 2016;139-43. doi: 10.3233/NPM-16915084.
75. Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. *Int J Lab Hematol*. 2016;38:505-513. doi: 10.1111/ijlh.12528.
76. Adcock DM, Mammen J, Nair SC, De Lima Montalvao SA. Quality laboratory issues in bleeding disorders. *Haemophilia*. 2016;22(5),84-89. doi: 10.1111/hae.12991
77. Belley A, Robson R, Francis JL, Adcock DM, Tiefenbacher S, Rubino CM, Moeck G, Sylvester D, Dudley MN, Loutit J. Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory. *Antimicrobial Agents and Chemotherapy*. 2017 Jan 24;61(2). Doi:10.1128/aac.01968-16.
78. Moore GW, Van Cott EM, Cutler JA, Mitchell MJ, Adcock DM. Recommendations for clinical laboratory testing of activated protein C resistance. *J Thrombosis and Haemostasis*. Submitted.
79. Adcock DM, Favalaro EJ, Lippi G. Critical Pre-examination Variables in the Hemostasis Laboratory and Their Quality Indicators. *Clinical Biochemistry* 2016;49(18):1315-1320.
80. Lima-Oliveri G, Adcock D, Salvagno GL, Favalaro EJ, Lippi G. Mixing of thawed coagulation samples prior to testing: is any technique better than another. *Clinical Biochemistry* 2016;49(18):1399-1401.
81. Lippi G, Bowen AR, Adcock DM. Re-engineering laboratory diagnostics for preventing preanalytical errors. *Clinical Biochemistry* 2016;49(18):1313-1314.
82. Bowen AR, Adcock DM. Blood collection tubes as medical devices: The potential to affect assays and proposed verification and validation processes for the clinical laboratory. *Clinical Biochemistry* 2016;49(18):1321-1330.
83. Castellone DD, Adcock DM. Factor VIII activity and inhibitor assays in the diagnosis and treatment of hemophilia A. *Semin Thromb Hemost*; 2017, 43:320-330.
84. Adcock DM, Gosselin. Laboratory assessment of hemostatic and anticoagulant therapy, Preface. *Semin Thromb Hemost* 2017, 43:242.
85. Lippi G, Adcock D, Simundic AM, Tripodi A, Favalaro EJ. Critical laboratory values in hemostasis: towards consensus. *Ann Med*. 2017 Sep;49(6):455-461. doi: 10.1080/07853890.2016.1278303
Annals of Medicine; 2016: DOI: 10.1080/07853890.2016.1278303.
86. Gosselin RC, Douxfil J, Adcock D. Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACs). *Hamostaseologie* 2017;37(4). doi: 10.5482/HAMO-17-01-0002
87. Goodwin A, Adcock D. Letter to the Editor. *New Eng J Med*. 2017;377:2297-2209

88. Gosselin RC, Adcock D, Bates S, Douxfils J, Favaloro E, Gouin-Thibault I, Lindhoff-Last E, Kitchen S. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants (DOACs). *Thromb Haem*, 2018 118(03): 437 - 450.
89. Gosselin RC, Douxfil J, Adcock D. Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACs). *Phlebologies* 2018;47.
90. Adcock DM, Strandberg K, Shima M, Marlar RA. Advantages, disadvantages and optimization of one-stage chromogenic factor activity assays in haemophilia A and B. *Int J Lab Hem*. 2018:1-9 DOI:10.1111/ijlh.12877.
91. Adcock DM, Rasulnia M, Holot N, Cooper DL. Educational needs of hematologists and laboratory professionals regarding factor activity assays. *Journal of Blood Medicine* 2018;9:51-59.

PUBLISHED GUIDELINES AND BOOK CHAPTERS:

1. Adcock DM, Marlar RA. The coagulation and hematologic disorders associated with liver disease. In: *Complications of Chronic Liver Disease*, Year Book Medical Publishers, Inc. 1992:268-294.
2. Marlar RA, Adcock DM. Hypercoagulability. In: Wood M, Bunn P, Eds. *Hematology – Oncology Secrets*, 2nd Ed. 1998. Hanley and Belfus Inc.
3. Arkin CF, Adcock DM, Day HJ Carroll JJ, Joist JH, Lenahan JG, Marlar RA, Triplett DA. Procedure for the determination of fibrinogen in plasma; approved guideline-second edition. NCCLS document H30-A2 (ISBN). 1998.
4. Marlar RA, Adcock DM, Arkin CF, Day JH, Carroll JJ, Joist JH, Lenahan JG, Triplett DA. Assays of von Willebrand factor antigen and ristocetin cofactor activity; approved guideline. NCCLS document H51-A (ISBN 1-56238-473-2). 2002;22(20).
5. Arkin CF, Adcock DM, Ernst DJ, Marlar RA, Parish GT, Szamosi DI, Warunek DJ. Collection, transport and processing of blood specimens for testing plasma-based coagulation assays; Approved guideline – fourth edition. NCCLS document H21-A4 (ISBN 1-56238-521-6). 2003.
6. Kiechle FL, Adcock DM, Davis CM, Ramirez N, Schwarz J, Tursky CL. So you're going to collect a blood specimen: An introduction to phlebotomy. Tenth Edition. College of American Pathologists. Northfield, IL. 2003. Eleventh Edition 2005; Thirteenth Edition 2007.
7. Davis BH, Machin SJ, Adcock DM, LaDuca FM, Michaud GY, Rabinovitch A, Stetler-Stevenson M. Performance of the bleeding time test; Approved Guideline – Second Edition. CLSI document H45-A2, Vol. 18, No. 0 (ISBN 1-56238-571-2; ISSN 0273-3099). 2005
8. Adcock DM, Brein WF, Duff SL, Johnston M, Kitchen S, Marlar RA, Ng VL, van den Besselaar T, Woodhams BJ. Procedures of Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline. CLSI document H54-A (ISBN 1-56238-000-0; ISSN 0273-3099). 2005.
9. Adcock DM, Jensen R, Johns CS, Macy PA. *Coagulation Handbook*, Second Edition. September 2002. Third Edition. January 2007.

10. Adcock DM, Hoefner DM, Kottke-Marchant K, Marlar RA, Szamosi DI, Warunek DJ. Collection transport and processing of blood specimens for testing plasma-based coagulation assays' Approved guideline – fifth edition. NCCLS document H21-A5.
11. Gardiner C Adcock DM, Carrington LR, Kottke-Marchant K, Marlar RA, McGlasson DL, Fisher Trumbull K, Wheeler JL, Biddle RL, Daniele C. Protocol for the valuation, validation, and implementation of coagulometers; Approved guideline. NCCLS document H57-A, Vol.28, No. 4 (ISBN 1-5623-656-5; ISSN 0273-3099). 2008.
12. Adcock DM. *Sample integrity and pre-analytical variables*. In: Preston, Kitchen, Olson, Eds. Quality in Laboratory Hemostasis and Thrombosis. Oxford, UK:Wiley-Blackwell. 2008.
13. Olson JD, Adcock DM, Bush TA, deMoerloose P, Gardiner C, Ginyard VR, Grimaux M. Quantitative D-dimer for the exclusion of venous thromboembolic disease; Proposed guideline. CLSI document H59-P, Vol. 30, No. 9 (ISBN 1-56238-723-5; ISSN 0273-3099). 2010.
14. Adcock DM. *Sample collection and processing in hemostasis*. In: Kottke-Marchant K, Davis BG, Eds. Laboratory Hematology Practice. Wiley-Blackwell. 2012, Chapter 31.
15. Kiechle FL, Adcock (Funk) DM, Rosser Rsesok-Pizzini D, Trusky CL. So you're going to collect a blood specimen: An introduction to phlebotomy. Tenth Edition. College of American Pathologists. Northfield, IL. Fourteenth Edition 2013.
16. Bowen RAR, Adcock DM. Interferences from Blood sampling Device materials on Clinical Assays. Part 1. In Pre Examination Procedures in Laboratory Diagnostics. Preanalytical Aspects and their Impact on the Quality of Medical Laboratory Results. WG Gruder editor. DeGruyter. 2015;170-204.
17. Bowen RAR, Adcock DM. Interferences from Blood sampling Device materials on Clinical Assays. Part 2. In Pre Examination Procedures in Laboratory Diagnostics. Preanalytical Aspects and their Impact on the Quality of Medical Laboratory Results. WG Gruder editor. DeGruyter. 2015;205-216.
18. Krishnan J, Adcock DM. Sample Collection and Processing. An algorithmic Approach to Hemostasis Testing. Kandice Kottke-Marchant. CAP Press. Second Edition. 2016;43-54.
19. Adcock DM, Moser KA, Dong C. Thrombotic Microangiopathies. An Algorithmic Approach to Hemostasis Testing. Kandice Kottke-Marchant. CAP Press. Second Edition. 2016;337-56.
20. Adcock DM, Moser KA. Mechanism and Monitoring of Anticoagulant Agents. An Algorithmic Approach to Hemostasis Testing. Kandice Kottke-Marchant. CAP Press. Second Edition. 2016;379-402.
21. Adcock DM, Poirier BF. Screening Coagulation Assays, Factor XIII and D-Dimer. Management of Bleeding Patients. Springer. 2016;3-16.

ABSTRACTS:

1. Brozna JP, Adcock DM, Marlar RA, Radmacher J. Correlation of monocyte-associated tissue factor activity with the development of disseminated intravascular coagulation. Blood 1989. 74(suppl 1) 388.
2. Kelly JP, Murray RS, Adcock DM, Rosenberg NL. Intravascular lymphomatosis related to Epstein-Barr virus in CNS tissue. American Association of Neurology 1988.

3. Johnston M, Adcock DM. The use of frozen plasma calibrants to standardize the international normalized ratio (INR). *Thromb Haemost* 1999;82(suppl):544.
4. Ericson D, Lien S, Mortari F, St. Cyr J, Rao G, Adcock DM, Viacell LLC, Techne, Inc. Ribose preserves aggregation in apheresis platelets. *Blood*. 2003;102(11):Abstract #3953.
5. Bethel M, Adcock DM, Ramanathan R. A comparison of calibration curves using unfractionated heparin, Enoxaparin, Dalteparin and Fondaparinux in a chromogenic anit-FXa assay. *J Thromb Haemost* 2005:0711.
6. Bethel M, Adcock DM, Ramanathan R. Intrinsic factor responsiveness of an aPTT reagent is significantly influenced by the type of factor deficient plasma used. *J Thromb Haemost*; 2005:1901.
7. Bethel M, Adcock DM, Zalevsky J, Young M, Fagrell B. Polythyle glycol-induced prolongation of aPTT in two biopharmaceuticals. *Int Jnl Lab Hem*, 2007;29(Suppl. 1),46-112.
8. Moll S, Soriano C, Deam AM, Mooberry M, Adcock DM. Once weekly subcutaneous ports for the administration of low molecular weight heparin: a prospective pharmacodynamics study. *J Throm Thrombolys* 2011,31:375.
9. Lippi G, Salvagno GL, (Adcock) Funk DM, Guidi GC, Favaloro EJ. Experimental study of blood tubes under-filling for routine coagulation testing. *Biochemia Medica. In Press*.
10. Teruya J, Teruya M, Soundar E, Nguyen K, Hui SKR, Eldin K, (Adcock) Funk DM. Oral abstract: PIVKA-II correlates with PT INR but not protein C or protein S level among newborns. *Intl Jnl Lab Hem* 2012;34(Suppl. 1),1-180.
11. Hawes EM, Deal AM, Jeanneret C, Miller A, Funk-Adcock D, Gosselin R, Whinna H, Moll S. A prospective pharmacodynamics study evaluating peak and trough coagulation test results in patients on therapeutic doses of dabigatran. *THSNA* 2012.
12. Bern M, Adcock DM. Thromboembolism Prophylaxis: Is very low fixed dose warfarin an equivalent postoperative regimen? *Am Academy of Orthopedic Surgeons* 2012.
13. Lippi G, Funk DM, Favaloro EJ. Discard tube for coagulation testing: The debate continues. *Blood Coagul Fibrinolysis* 2012 Sep;23(6):572-3.